[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:primary-cutaneous-t-cell-non-hodgkin-lymphoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":176,"states":177},"Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",27,25,[8,16,22,29,35,41,47,53,59,65,71,77,83,89,95,101,107,113,119,125,131,137,143,149,155,161,168],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07047885","Ropeginterferon in Patients w\u002FCutaneous T-Cell Lymphoma (CTCL)",[12],"Phase 1","RECRUITING","2026-08-26T02:18:57.189473Z","2026-05-05T02:43:29.464550Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT04234048","Phase 1 Trial of ST-001 nanoFenretinide in Relapsed\u002FRefractory T-cell Non-Hodgkin Lymphoma",[12],"2026-08-26T02:18:21.216897Z","2026-05-05T02:43:29.023064Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT06698822","A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA",[26],"Phase 2","2026-08-26T02:16:28.221034Z","2026-05-05T02:43:28.732498Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT04848064","Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia\u002FLymphoma",[12],"2026-08-26T02:18:44.395098Z","2026-05-05T02:43:27.813290Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06733441","A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma",[12],"2026-08-03T02:36:50.517616Z","2026-05-05T02:43:27.594078Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT06854653","A Phase 2 Study of PTX 100 in Patients With Relapsed\u002FRefractory CTCL",[26],"2026-08-26T02:17:03.534765Z","2026-05-05T02:35:31.681316Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT04256018","Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome",[26],"2026-08-26T02:16:05.813655Z","2026-05-05T02:43:28.661336Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT07356245","Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma",[26],"2026-08-26T02:17:33.002248Z","2026-05-05T02:43:27.624777Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT07192471","A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma",[12],"2026-08-26T02:17:59.904383Z","2026-07-05T05:32:16.661363Z",{"nct_id":66,"title":67,"phases":68,"status":13,"updated_at":69,"content_modified":70},"NCT06712810","Q702 for the Treatment of Patients With Hematologic Malignancies",[12],"2026-08-26T02:16:20.336282Z","2026-05-05T02:43:29.581486Z",{"nct_id":72,"title":73,"phases":74,"status":13,"updated_at":75,"content_modified":76},"NCT07283822","Amping up With PemJAK",[26],"2026-08-26T02:15:03.757872Z","2026-05-05T02:43:29.349629Z",{"nct_id":78,"title":79,"phases":80,"status":13,"updated_at":81,"content_modified":82},"NCT05996185","Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma",[26],"2026-08-26T02:16:52.995882Z","2026-05-05T02:43:28.341848Z",{"nct_id":84,"title":85,"phases":86,"status":13,"updated_at":87,"content_modified":88},"NCT05544968","Anti-CD30 biAb-AATC in Patients With Relapsed\u002FRefractory CD30 Positive Hematopoietic Malignancies",[12],"2026-08-26T02:17:20.511551Z","2026-05-05T02:43:27.997953Z",{"nct_id":90,"title":91,"phases":92,"status":13,"updated_at":93,"content_modified":94},"NCT05967416","Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma",[12],"2026-08-26T02:15:43.339060Z","2026-05-05T02:43:27.815843Z",{"nct_id":96,"title":97,"phases":98,"status":13,"updated_at":99,"content_modified":100},"NCT07055477","A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)",[12],"2026-08-26T02:18:46.137046Z","2026-05-05T02:43:27.673466Z",{"nct_id":102,"title":103,"phases":104,"status":13,"updated_at":105,"content_modified":106},"NCT07195916","A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies",[12],"2026-08-26T02:17:45.190188Z","2026-05-05T02:43:27.041939Z",{"nct_id":108,"title":109,"phases":110,"status":13,"updated_at":111,"content_modified":112},"NCT05010005","A Study of Ruxolitinib and Duvelisib in People With Lymphoma",[12],"2026-08-26T02:16:01.079019Z","2026-05-05T02:43:26.685721Z",{"nct_id":114,"title":115,"phases":116,"status":13,"updated_at":117,"content_modified":118},"NCT04045470","A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma",[],"2026-08-26T02:18:48.678868Z","2026-05-05T02:43:28.124870Z",{"nct_id":120,"title":121,"phases":122,"status":13,"updated_at":123,"content_modified":124},"NCT04014374","Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab",[],"2026-08-26T02:16:08.402952Z","2026-05-13T02:55:06.182295Z",{"nct_id":126,"title":127,"phases":128,"status":13,"updated_at":129,"content_modified":130},"NCT00177268","Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research",[],"2026-08-26T02:17:18.747857Z","2026-05-13T02:55:06.031740Z",{"nct_id":132,"title":133,"phases":134,"status":13,"updated_at":135,"content_modified":136},"NCT02840747","Tissue Repository: CTCL Collection Protocol",[],"2026-08-26T02:16:33.772093Z","2026-05-13T02:55:06.102573Z",{"nct_id":138,"title":139,"phases":140,"status":13,"updated_at":141,"content_modified":142},"NCT03932279","Characterization of the Microbiome in Cutaneous T Cell Lymphoma",[],"2026-08-26T02:18:02.701182Z","2026-05-13T02:55:06.180365Z",{"nct_id":144,"title":145,"phases":146,"status":13,"updated_at":147,"content_modified":148},"NCT01087333","Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment",[],"2026-08-26T02:16:51.982021Z","2026-05-13T02:55:06.067187Z",{"nct_id":150,"title":151,"phases":152,"status":13,"updated_at":153,"content_modified":154},"NCT04087629","StrataCTX® as a Steroid Sparing Device",[],"2026-08-26T02:18:03.638950Z","2026-05-05T02:43:27.679383Z",{"nct_id":156,"title":157,"phases":158,"status":13,"updated_at":159,"content_modified":160},"NCT06860880","Combating Cancer-Related Fatigue: A Personalized Supportive Care Program",[],"2026-08-26T02:16:57.705506Z","2026-05-05T02:43:28.349178Z",{"nct_id":162,"title":163,"phases":164,"status":165,"updated_at":166,"content_modified":167},"NCT07691450","Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma",[12],"NOT_YET_RECRUITING","2026-08-26T02:16:42.787115Z","2026-07-19T19:36:05.157190Z",{"nct_id":169,"title":170,"phases":171,"status":173,"updated_at":174,"content_modified":175},"NCT05589896","A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies",[172],"Phase 1\u002FPhase 2","ACTIVE_NOT_RECRUITING","2026-08-03T03:35:37.456806Z","2026-05-05T02:43:29.711460Z",[],[178,182,186,190,194,197,201,204,207,210],{"state":179,"count":180,"slug":181},"New York",10,"new-york",{"state":183,"count":184,"slug":185},"California",9,"california",{"state":187,"count":188,"slug":189},"Texas",6,"texas",{"state":191,"count":192,"slug":193},"Florida",4,"florida",{"state":195,"count":192,"slug":196},"Massachusetts","massachusetts",{"state":198,"count":199,"slug":200},"Michigan",3,"michigan",{"state":202,"count":199,"slug":203},"New Jersey","new-jersey",{"state":205,"count":199,"slug":206},"Ohio","ohio",{"state":208,"count":199,"slug":209},"Pennsylvania","pennsylvania",{"state":211,"count":199,"slug":212},"Tennessee","tennessee"]